Fengsheng Che - Sihuan Pharmaceutical Chairman
SHPHFDelisted Stock | USD 0.1 0.00 0.00% |
Chairman
Dr. Che Fengsheng is Executive Chairman of the Board of the Company. He is a cofounder of the Group and is responsible for the overall management, strategic planning and business development of the Group and is instrumental to the Groups growth and business expansion since its establishment in 2001. Prior to the Groups establishment, Dr. Che had more than 8 years of experience as a medical doctorneurologist and 20 years of experience in the sales and marketing of pharmaceutical products and the management of pharmaceutical companies. From 1997 to 2001, Dr. Che was general manager of Hainan Kang Tong Pharmaceutical Co., Ltd where he was in charge of the companys overall management. From 1995 to 1997, Dr. Che was the assistant general manager and vice manager of Shenzhen City New Special Pharmaceutical Products Co., Ltd. where he was responsible for the marketing and overall management of the companys business. Between 1993 and 1995, Dr. Che was the product promotions manager of Shenzhen City Healthcare Pharmaceutical Company and East China Regional manager, in charge of sales and marketing. From 1991 to 1993, Dr. Che held the position of chief neurologist and lecturer in First Military Medical University, Zhu Jiang Hospital, Guangzhou City, PRC. Dr. Che was a neurologist and an assistant lecturer at the Fourth Military Medical University in Xian City, PRC from 1990 to 1991 and at the Fourth Military Medical University, Xi Jing Hospital in Xian City, PRC from 1984 to 1987 respectively. since 2014.
Age | 61 |
Tenure | 10 years |
Professional Marks | Ph.D |
Phone | 852 3628 3911 |
Web | https://www.sihuanpharm.com |
Sihuan Pharmaceutical Management Efficiency
Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Sihuan Pharmaceutical Holdings has accumulated 844.75 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 6 records | CHAIRMAN Age | ||
Jack Bendheim | Phibro Animal Health | 77 | |
Judy Schmeling | Canopy Growth Corp | 60 | |
Michael Singer | Aurora Cannabis | 56 | |
Ruben Minski | Procaps Group SA | 72 | |
Ronald Funk | Aurora Cannabis | 63 | |
Mark Iwicki | Kala Pharmaceuticals | 58 |
Management Performance
Return On Equity | -0.0487 | |||
Return On Asset | -4.0E-4 |
Sihuan Pharmaceutical Leadership Team
Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee | ||
Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director | ||
Yanling Chen, Joint Director | ||
Guili Miao, Chief CEO | ||
Kin Li, Joint Sec | ||
Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee | ||
Jionglong Zhang, Non-Executive Director | ||
Chengkon Shih, General Manager of Shandong Xuanzhu | ||
Feng Guo, Executive Director |
Sihuan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0487 | |||
Return On Asset | -4.0E-4 | |||
Profit Margin | (0.05) % | |||
Operating Margin | (0) % | |||
Current Valuation | 506.36 M | |||
Shares Outstanding | 9.33 B | |||
Shares Owned By Insiders | 55.02 % | |||
Shares Owned By Institutions | 4.21 % | |||
Price To Earning | 8.75 X | |||
Price To Book | 0.81 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Sihuan Pink Sheet
If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Stocks Directory Find actively traded stocks across global markets |